Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute Spinal Cord Injury
Osteoporosis · Spinal Cord Injuries
Enrolment: 40 · Results not recorded
Loading the evidence…
Biologic · Sclerostin inhibitor; inhibits sclerostin, increasing bone formation and decreasing bone resorption
1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Osteoporosis · Spinal Cord Injuries
Enrolment: 40 · Results not recorded
Osteoporosis · Osteoporosis Postmenopausal
Enrolment: 70 · Results not recorded
Postmenopausal Osteoporosis
Enrolment: 50 · Results not recorded
Postmenopausal Osteoporosis
Enrolment: 7180 · Results not recorded
Postmenopausal Osteoporosis
Enrolment: 252 · Results not recorded
Osteoporosis, Post-menopausal
Enrolment: 0 · Results not recorded
Osteopenia
Enrolment: 74 · Results not recorded
Osteoporosis
Enrolment: 24 · Results not recorded
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Complete spinal cord transection (chronic motor-complete spinal cord injury), with laminectomy-only sham
At 20 weeks after injury, vehicle-treated transected rats had lower bone mineral density at the distal femur, proximal tibia and lumbar spine (about -22, -15 and -9 per cent versus sham), reduced trabecular bone volume (-37.2 per cent) and connectivity (-53.2 per cent), reduced cortical thickness (…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.
Model: Motor-complete spinal cord injury with disuse bone loss
Spinal cord injury reduced distal femur bone mineral density by about 25% and trabecular bone volume by about 67%; sclerostin antibody completely prevented these losses, markedly increased bone formation, and restored osteocyte number and morphology.
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.